These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 9329608)

  • 1. The clinical value of cathepsin-D and TNF-alpha in bladder cancer patients.
    Salman T; el-Ahmady O; el-Shafee M; Omar S; Salman I
    Anticancer Res; 1997; 17(4B):3087-90. PubMed ID: 9329608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cathepsin-D and TNF-alpha in bladder cancer.
    Salman T; el-Ahmady O; el-Shafee M; Omar S; Salman I
    Dis Markers; 1996 Mar; 12(4):253-9. PubMed ID: 8718785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience.
    el-Ahmady O; Halim AB; el-Din AG
    Anticancer Res; 1999; 19(4A):2603-8. PubMed ID: 10470202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of cathepsin D in breast cancer and its clinical and histopathological correlations].
    Ramírez-Ortega MC; Frías-Mendívil M; Delgado-Chávez R; Meneses-García A; Carrillo-Hernández JF; Ramírez-Ugalde MT; Zeichner-Gancz I
    Rev Invest Clin; 1997; 49(5):361-8. PubMed ID: 9527695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of diagnostic and prognostic values of urinary interleukin-8, tumor necrosis factor-alpha, and leukocyte arylsulfatase-A activity in patients with bladder cancer.
    Koçak H; Oner-Iyidoğan Y; Koçak T; Oner P
    Clin Biochem; 2004 Aug; 37(8):673-8. PubMed ID: 15302609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cancer procoagulant and cathepsin D activity in blood serum in patients with bladder cancer].
    Szajda SD; Darewicz B; Kudelski J; Chlabicz M; Domel T; Chabielska E; Skrzydlewski Z
    Pol Merkur Lekarski; 2005 Jun; 18(108):651-3. PubMed ID: 16124376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel blood biomarkers of human urinary bladder cancer.
    Osman I; Bajorin DF; Sun TT; Zhong H; Douglas D; Scattergood J; Zheng R; Han M; Marshall KW; Liew CC
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3374-80. PubMed ID: 16740760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Quantification of bladder tumor antigen (BTA trak) and its correlation with bladder cancer grade and stage].
    Rodríguez Martínez JJ; Escaf Barmadah S; Allende MT; Raigoso P; Martín Benito JL; Pérez García FJ; Fernández Gómez JM
    Arch Esp Urol; 2000; 53(1):1-6. PubMed ID: 10730418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cathepsin D in diagnosis of neoplastic diseases].
    Warwas M; Taurowska E
    Postepy Hig Med Dosw; 1993; 47(4):277-88. PubMed ID: 8309853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGF, TNF-alpha and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer.
    Dalaveris E; Kerenidi T; Katsabeki-Katsafli A; Kiropoulos T; Tanou K; Gourgoulianis KI; Kostikas K
    Lung Cancer; 2009 May; 64(2):219-25. PubMed ID: 18845357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of bladder tumors and GA genotype of -308 nucleotide in tumor necrosis factor-alpha promoter with greater tumor necrosis factor-alpha expression.
    Jeong P; Kim EJ; Kim EG; Byun SS; Kim CS; Kim WJ
    Urology; 2004 Nov; 64(5):1052-6. PubMed ID: 15533517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Proteases and prostatic disease: cytosolic cathepsin D].
    Gómez Díaz ME; Ruibal-Morell A; Abascal García R
    Arch Esp Urol; 2001 Mar; 54(2):101-7. PubMed ID: 11341113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density.
    Lösch A; Schindl M; Kohlberger P; Lahodny J; Breitenecker G; Horvat R; Birner P
    Gynecol Oncol; 2004 Feb; 92(2):545-52. PubMed ID: 14766246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening and monitoring for bladder cancer: refining the use of NMP22.
    Ponsky LE; Sharma S; Pandrangi L; Kedia S; Nelson D; Agarwal A; Zippe CD
    J Urol; 2001 Jul; 166(1):75-8. PubMed ID: 11435827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
    Mahmoud RA; El-Gendi HI; Ahmed HH
    Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urine prothymosin-alpha as novel tumor marker for detection and follow-up of bladder cancer.
    Tzai TS; Tsai YS; Shiau AL; Wu CL; Shieh GS; Tsai HT
    Urology; 2006 Feb; 67(2):294-9. PubMed ID: 16461079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell cycle regulators in bladder cancer: relationship to schistosomiasis.
    Eissa S; Ahmed MI; Said H; Zaghlool A; El-Ahmady O
    IUBMB Life; 2004 Sep; 56(9):557-64. PubMed ID: 15590562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible correlation between polymorphism in the tumor necrosis factor-beta gene and the clinicopathological features of bladder cancer in Japanese patients.
    Nonomura N; Tokizane T; Nakayama M; Inoue H; Nishimura K; Muramatsu M; Okuyama A
    Int J Urol; 2006 Jul; 13(7):971-6. PubMed ID: 16882065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
    Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
    Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.